Core Insights - The company Baixinan-B (02185) announced that its subsidiary, Shanghai Antong Medical Technology Co., Ltd. (Antong), has successfully registered the Iberis Renal Denervation (RDN) system with the UK's Medicines and Healthcare products Regulatory Agency (MHRA) [1] - Antong has formed a strategic partnership with Bosheng International Group Ltd. (Bosheng) for the commercialization of the Iberis RDN system across multiple regions, including the EU, Asia-Pacific, and Latin America [1] - The Iberis RDN system is currently the only RDN product globally approved for both transradial access (TRA) and transfemoral access (TFA), enhancing safety, efficacy, and cost-effectiveness of the procedure [1] Company Overview - Bosheng is a company registered in Bermuda and is a subsidiary of Shenzhen Stock Exchange-listed Blue Sail Medical Co., Ltd. (stock code: 002382), focusing on cardiovascular business [2] - Bosheng operates globally with its headquarters in Singapore and European headquarters in Morges, Switzerland, aiming to meet healthcare needs through a combination of direct sales and a global distribution network [2] - The company is committed to supporting medical education and advancing patient care by organizing training courses, scientific summits, and related activities at international and national levels [2]

Core Viewpoint - The company announced that its subsidiary, Shanghai Antong Medical Technology Co., Ltd., has successfully registered the Iberis® Renal Denervation (RDN) System with the UK's Medicines and Healthcare products Regulatory Agency (MHRA) [1] Group 1: Product Development - The Iberis® RDN System is the only globally approved renal denervation product that can be used via both transradial access (TRA) and transfemoral access (TFA) methods [1] - TRA enhances the safety, efficacy, and cost-effectiveness of RDN procedures [1] Group 2: Strategic Partnerships - The company has formed a strategic partnership with Bosheng International Group Limited to commercialize the Iberis® RDN System across multiple regions, including but not limited to EU countries, the Asia-Pacific region, and Latin America (LATAM) [1] Group 3: Regulatory Milestones - The Iberis® RDN System received its CE mark in Europe in 2016, indicating its compliance with health and safety standards [1]

本 公 告 乃 由 上 海 百 心 安 生 物 技 術 股 份 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」）自 願 作 出，以 向 本 公 司 股 東 及 潛 在 投 資 者 提 供 有 關 本 集 團 最 新 業 務 發 展 情 況 的 最 新 資 料。 Shanghai Bio-heart Biological Technology Co., Ltd. 上海百心安生物技術股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：2185） 自願公告 IBERIS® RDN系統在英國註冊 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不會就本公告全部或任何部分內容而產生或因依賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 本 公 司 董 事 會（「董事會」）欣 然 宣 佈，最 近，本 公 司 附 屬 公 司 上 海 安 通 醫 療 科 技 有 限 公 司（「安 通」）研 發 的Iber ...

Core Viewpoint - 百心安-B's stock price increased by over 4% following the announcement of the successful market entry and commercialization of the Iberis RDN system in Switzerland [1] Group 1: Company Developments - 百心安-B's subsidiary, Shanghai Antong Medical Technology Co., Ltd., has successfully completed the first commercial procedure using the Iberis RDN system at Basel University Hospital [1] - The procedure reported no complications or adverse events, indicating a positive outcome for the initial commercialization [1] - Antong has formed a strategic partnership with Bosheng International Group to commercialize the Iberis RDN system across multiple regions, including the EU, Asia-Pacific, and Latin America [1] Group 2: Product Information - The Iberis RDN system is the only renal denervation (RDN) product globally approved for both transradial access (TRA) and transfemoral access (TFA) methods [1] - The TRA method enhances the safety, efficacy, and cost-effectiveness of RDN procedures [1] - The ultimate goal of the company is to provide outpatient RDN surgeries for patients worldwide, with the Iberis RDN system having received CE marking in Europe in 2016 [1]

Core Viewpoint - Baixinan-B (02185.HK) has seen a significant increase in its stock price, rising over 4% to reach 7.78 HKD with a trading volume of 4.5541 million HKD [1] Summary by Category - Stock Performance - Baixinan-B's stock price increased by 4.57% [1] - The current trading price is 7.78 HKD [1] - The trading volume recorded is 455.41 million HKD [1]

Major Events - Minglue Technology (02718) plans to offer 7.219 million Class A shares globally from October 23 to October 28, with cornerstone subscriptions amounting to $59 million [1] - Wisco Properties (00230) received a privatization offer from Wisco Hong Kong at a premium of approximately 104.08%, with trading resuming on October 24 [1] - Junyu Foundation (01757) was acquired by China Venture Capital Holdings for 75% of its shares at a discount of about 79.06%, with trading resuming on October 24 [1] - Kangda Foods (00834) was acquired by Gaosi Shi for approximately 54.69% of the company’s shares at a premium of about 16.23%, with trading resuming on October 24 [1] - Hutchison China MediTech (00013) presented data on HMPL-A251 at the AACR-NCI-EORTC International Conference on Molecular Targeted and Cancer Therapeutics [1] - Giant Bio (02367) received a medical device registration certificate for its Type I α1 collagen lyophilized fiber product [1] - Yiming Anke-B (01541) completed the first patient dosing in the Phase IB/II clinical trial of IMM2510 combined with IMM01 [1] - Heng Rui Medicine (01276) received approval to conduct clinical trials for injection of Rikan Trastuzumab [1] - Hansoh Pharmaceutical (03692) had its application for HS-10365 capsule marketing approval accepted by the National Medical Products Administration [1] - Baixin An-B (02185) completed market access and the first commercial surgery for the IBERIS® RDN system in Switzerland [1] - Haotian International Construction Investment (01341) purchased a total of 646 units of Ethereum as of October 23 [1] Share Buybacks/Reductions - Cornerstone Pharmaceuticals-B (02616) saw CEO Yang Jianxin and senior management purchase an additional 1 million shares [2] - Midea Group (00300) repurchased 1.3434 million A shares for approximately 99.998 million yuan on October 23 [2] - China Communications Construction (01800) repurchased 119.45 million A shares for approximately 10.5994 million yuan on October 23 [2] - Mengniu Dairy (02319) repurchased 700,000 shares for approximately 10.0692 million HKD on October 23 [2] - Lianlian Digital (02598) spent about 7.5555 million HKD to repurchase 967,000 shares on October 23 [2] - Lianyi Rong Technology-W (09959) repurchased 2.47 million shares for approximately 7.4137 million HKD on October 23 [2] - Heng Rui Medicine (01276) repurchased 97,500 A shares for approximately 6.2808 million yuan on October 23 [2] - Gushengtang (02273) repurchased 19,860 shares for approximately 5.8634 million HKD on October 23 [2] Operating Performance - Ping An Good Doctor (01833) reported total revenue of approximately 3.725 billion yuan for the first three quarters, a year-on-year increase of 13.6%, and plans to continue expanding AI technology to enhance medical service efficiency and quality [2] - Sands China Ltd. (01928) reported a 7.5% year-on-year increase in net revenue to $1.9 billion for the third quarter [2] - Livzon Pharmaceutical (01513) announced a net profit attributable to shareholders of 1.754 billion yuan for the first three quarters, a year-on-year increase of 4.86% [2] - China Railway Construction (01186) signed new contracts totaling 1.518765 trillion yuan in the first three quarters, a year-on-year increase of 3.08% [2] - Prada (01913) reported net revenue of 4.07 billion euros for the first three quarters, a year-on-year increase of 9% [2] Additional Performance Metrics - Baio Family Interactive (02100) reported 10.2 million active accounts in the third quarter, a year-on-year increase of 37.8% [3] - Anton Oilfield Services (03337) secured new orders worth 1.273 billion yuan in the third quarter [3]

Core Viewpoint - The announcement highlights the successful market entry and first commercial procedure of the Iberis RDN system in Switzerland, marking a significant milestone for the company and its strategic partner [1] Group 1: Product Development and Approval - The Iberis RDN system, developed by Shanghai Antong Medical Technology Co., Ltd., has completed market access and the first commercial surgery in Switzerland [1] - The system is the only renal denervation (RDN) product globally approved for both transradial access (TRA) and transfemoral access (TFA) methods, enhancing safety, efficacy, and cost-effectiveness [1] - The company aims to provide outpatient RDN surgeries for patients worldwide [1] Group 2: Strategic Partnerships - Antong has formed a strategic partnership with Bosheng International Group, covering multiple regions including EU countries, Asia-Pacific, and Latin America (LATAM) for the commercialization of the Iberis RDN system [1] - The collaboration is expected to support the broader distribution and adoption of the Iberis RDN system in various international markets [1] Group 3: Safety and Efficacy - The first commercial procedure at Basel University Hospital reported no complications or adverse events, indicating a positive initial outcome for the Iberis RDN system [1] - The TRA method utilized in the procedure is noted to make RDN safer and more effective compared to traditional methods [1]

Core Viewpoint - The announcement highlights the successful market entry and commercialization of the Iberis RDN system in Switzerland, marking a significant milestone for the company and its strategic partnership with 柏盛国际集团有限公司 [1] Group 1: Product Development and Approval - The Iberis RDN system, developed by the company's subsidiary 上海安通医疗科技有限公司, has completed market access and the first commercial procedure in Switzerland [1] - The system is the only renal denervation (RDN) product globally approved for both transradial access (TRA) and transfemoral access (TFA) methods, enhancing safety, efficacy, and cost-effectiveness [1] - The ultimate goal of the company is to provide outpatient RDN procedures for patients worldwide [1] Group 2: Strategic Partnerships - A strategic partnership has been established between 安通 and 柏盛 for the commercialization of the Iberis RDN system, covering multiple regions including the EU, Asia-Pacific, and Latin America [1] - The first commercial procedure was performed at 巴塞尔大学医院, with no reported complications or adverse events [1] Group 3: Regulatory Milestones - The Iberis RDN system received CE marking in Europe in 2016, indicating its compliance with health, safety, and environmental protection standards [1]

Core Viewpoint - The announcement highlights the successful market entry and commercialization of the Iberis® RDN system by the company's subsidiary, Shanghai Antong Medical Technology Co., Ltd, in Switzerland, marking a significant milestone in the company's product development and market strategy [1] Group 1: Product Development - The Iberis® RDN system has completed market access and the first commercial procedure in Switzerland, performed at the University Hospital of Basel, with no reported complications or adverse events [1] - The Iberis® RDN system is the only renal denervation (RDN) product globally approved for both transradial access (TRA) and transfemoral access (TFA) methods, enhancing safety, efficacy, and cost-effectiveness [1] Group 2: Strategic Partnerships - The company has established a strategic partnership with Bosheng International Group for the commercialization of the Iberis® RDN system, covering multiple regions including the EU, Asia-Pacific, and Latin America [1] Group 3: Regulatory Approvals - The Iberis® RDN system received CE marking in Europe in 2016, indicating its compliance with health, safety, and environmental protection standards for products sold within the European Economic Area [1]

本 公 告 乃 由 上 海 百 心 安 生 物 技 術 股 份 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」）自 願 作 出，以 向 本 公 司 股 東 及 潛 在 投 資 者 提 供 有 關 本 集 團 最 新 業 務 發 展 情 況 的 最 新 資 料。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不會就本公告全部或任何部分內容而產生或因依賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 Shanghai Bio-heart Biological Technology Co., Ltd. 上海百心安生物技術股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：2185） 自願公告 IBERIS® RDN系統於瑞士的首個商業案例 承董事會命 本 公 司 董 事 會（「董事會」）欣 然 宣 佈，最 近，本 公 司 附 屬 公 司 上 海 安 通 醫 療 科 技 有 限 公 司（「安 通 ...